Residency · Residency · Respirology

Lung Transplantation - Indications and Complications

Overview

Current Landscape

Lung transplantation has matured into an established therapeutic option for patients with end-stage lung disease, with approximately 4,500 procedures performed annually worldwide according to the International Society for Heart and Lung Transplantation (ISHLT) Registry data from 2023. Overall median survival following lung transplantation is approximately 6.5 years, with 1-year survival of 85% to 90% and 5-year survival of 55% to 60%. These outcomes reflect steady improvement over time, attributable to advances in donor management and organ preservation, refined surgical techniques, more effective immunosuppressive regimens, and comprehensive post-transplant surveillance and management protocols. Bilateral lung transplantation now accounts for more than 75% of procedures performed and is associated with better long-term survival compared with single lung transplantation for most indications.

Indications by Disease

The spectrum of diseases for which lung transplantation is performed has shifted over recent decades. Interstitial lung disease, including idiopathic pulmonary fibrosis, has become the most common indication and carries the highest waitlist mortality due to the often rapid and unpredictable progression of IPF. Chronic obstructive pulmonary disease, historically the most common indication, is now second in many registries. Cystic fibrosis is the third most common indication and is notable for excellent post-transplant outcomes. Pulmonary arterial hypertension has become a less common indication due to the expanded armamentarium of effective medical therapies, though transplantation remains indicated for patients with refractory disease despite maximal combination therapy. Other indications include non-CF bronchiectasis, lymphangioleiomyomatosis, sarcoidosis, and re-transplantation for chronic lung allograft dysfunction.

Referral and Listing Criteria

General ISHLT 2021 Guidelines for Referral

The 2021 ISHLT consensus document provides a framework for transplant referral centered on three fundamental criteria. The patient should have a greater than 50% risk of death from their lung disease within 2 years without transplant. The patient should have a greater than 80% likelihood of surviving at least 90 days after transplantation. And the patient should have a greater than 80% likelihood of 5-year post-transplant survival from a general medical perspective, assuming adequate graft function. These criteria balance the imperative to offer transplantation to those who need it most urgently with the obligation to ensure that the scarce resource of donor organs is allocated to those most likely to benefit.

Disease-Specific Referral Triggers

Disease-specific referral triggers guide the timing of referral to a transplant center. For COPD, referral should be considered when the BODE index reaches 5 to 6, when frequent exacerbations require hospitalization and result in acute hypercapnic respiratory failure, when FEV1 falls below 25% predicted with DLCO below 20%, or when functional status is progressively limited despite maximal medical therapy including pulmonary rehabilitation. For IPF, referral triggers include DLCO below 40% predicted, FVC decline of 10% or greater over 6 months, desaturation below 88% on 6-minute walk test or a decline in walk distance exceeding 50 meters, hospitalization for respiratory decline, and histopathologic or radiographic UIP pattern. For cystic fibrosis, referral criteria include FEV1 below 30% predicted or rapid decline, 6-minute walk distance below 400 meters, pulmonary hypertension, increasing antibiotic resistance, increasing hospitalization frequency, and massive hemoptysis requiring bronchial artery embolization. For pulmonary arterial hypertension, referral is indicated when patients remain in WHO functional class III or IV despite maximal combination therapy including intravenous prostacyclin, with a cardiac index below 2 L/min/m2, right atrial pressure exceeding 15 mmHg, or 6-minute walk distance below 350 meters.

Absolute Contraindications (ISHLT 2021)

Absolute contraindications to lung transplantation include recent malignancy with insufficient disease-free interval (generally less than 2 to 5 years depending on tumor type and biology), significant untreatable dysfunction of another major organ system (unless combined organ transplantation is considered), non-curable chronic extrapulmonary infection (including active tuberculosis, chronic active hepatitis B or C with liver damage, or HIV with detectable viral load), significant chest wall or spinal deformity expected to cause severe restriction after transplantation, active substance abuse including tobacco use (with most centers requiring a minimum 6-month abstinence period), documented non-adherence to medical therapy or inadequate social support systems, and severely limited functional status with poor rehabilitation potential. Body mass index of 35 or greater is a relative contraindication at many centers, with some programs using a threshold of 30.

Relative Contraindications

Relative contraindications require individualized assessment and vary among transplant centers. Advanced age, with most centers using 65 to 70 years as the upper limit for bilateral transplantation, is a common relative contraindication. Severe osteoporosis with vertebral fractures increases perioperative risk. Mechanical ventilation or ECMO as a bridge to transplant is increasingly accepted at experienced, high-volume centers but remains controversial. Colonization with highly resistant organisms, particularly Burkholderia cenocepacia in CF patients, is considered an absolute contraindication at some centers due to the extremely high post-transplant mortality associated with this organism. Prior thoracic surgery increases surgical complexity and operative time but does not preclude transplantation.

<image>A decision timeline for lung transplant referral and listing. Show a horizontal timeline from initial disease diagnosis to transplant. Phase 1 (Referral triggers): disease-specific criteria with icons for COPD (BODE >= 5-6), IPF (DLCO < 40%, FVC decline > 10%), CF (FEV1 < 30%), PAH (WHO FC III-IV despite IV prostacyclin). Phase 2 (Transplant evaluation): comprehensive assessment over 2-4 weeks including PFTs, 6MWT, RHC, CT chest, cardiac evaluation, psychosocial assessment, nutritional assessment, infectious disease screening. Phase 3 (Listing): Lung Allocation Score (LAS) calculation and active listing. Phase 4 (Waitlist): ongoing monitoring, optimization, bridge therapies if needed (ECMO, mechanical ventilation). Phase 5 (Transplant): donor matching, surgery. Phase 6 (Post-transplant): lifelong immunosuppression, surveillance, complication monitoring. Show common causes of waitlist mortality: IPF has highest waitlist mortality. Include LAS components.</image>

Surgical Considerations

Lung Allocation Score (LAS)

The Lung Allocation Score, implemented in the United States in 2005, fundamentally changed organ allocation by prioritizing medical urgency and predicted post-transplant survival over waiting time. The LAS integrates multiple clinical variables including the underlying diagnosis, FVC, pulmonary artery systolic pressure, 6-minute walk distance, oxygen requirements, age, body mass index, functional status, diabetes status, PCO2, and whether the patient is on continuous mechanical ventilation. The resulting score ranges from 0 to 100, with higher scores conferring higher priority on the waiting list. Patients with IPF tend to receive the highest LAS scores, consistent with their having the highest waitlist mortality, which in turn has facilitated more timely access to transplantation for this population.

Bilateral vs. Single Lung Transplant

The choice between bilateral and single lung transplantation depends on the underlying disease and patient-specific factors. Bilateral transplantation is mandatory for cystic fibrosis and bronchiectasis to avoid leaving a chronically infected native lung that would serve as a reservoir for recurrent allograft infection. It is also strongly preferred for pulmonary arterial hypertension and is increasingly favored for COPD and ILD based on evidence of better long-term outcomes. Single lung transplantation offers a faster surgical procedure with shorter ischemic time and may be appropriate for older patients with COPD or ILD, though in COPD, native lung hyperinflation may compress and compromise the transplanted graft. Heart-lung transplantation is rare in the modern era, reserved for Eisenmenger syndrome with irreparable cardiac defects or severe biventricular failure in the setting of advanced lung disease.

Ex Vivo Lung Perfusion (EVLP)

Ex vivo lung perfusion represents a transformative innovation in donor organ management. This technique involves normothermic perfusion and ventilation of donor lungs outside the body, enabling functional assessment and reconditioning of marginal donor organs that would otherwise be declined. EVLP has expanded the usable donor pool by 15% to 20%, addressing a critical bottleneck in organ availability. The technique is applicable to lungs from both donation after brain death (DBD) and donation after circulatory death (DCD) donors. Clinical trials including the HELP trial, the EXPAND trial, and the extensive Toronto experience have demonstrated that outcomes with EVLP-reconditioned lungs are comparable to those achieved with standard-criteria donors. Emerging applications of the EVLP platform include therapeutic delivery of gene therapy vectors, antimicrobial agents, and anti-inflammatory compounds during the perfusion period, potentially improving graft quality before implantation.

Immunosuppression

Standard Triple Therapy

The immunosuppressive regimen for lung transplant recipients follows a triple-drug strategy targeting different points in the T-cell activation and proliferation cascade. The calcineurin inhibitor, typically tacrolimus (which has largely supplanted cyclosporine), blocks T-cell activation by inhibiting the calcineurin-NFAT pathway; target trough levels are maintained at 8 to 15 ng/mL in the early post-transplant period, tapering to 5 to 10 ng/mL for long-term maintenance. The antiproliferative agent, most commonly mycophenolate mofetil at 1 to 1.5 g twice daily (with azathioprine as an alternative at 1 to 2 mg/kg/day), inhibits de novo purine synthesis and thereby suppresses lymphocyte proliferation. Corticosteroids provide broad anti-inflammatory and immunosuppressive effects: methylprednisolone is administered intravenously in the perioperative period, followed by oral prednisone initiated at approximately 0.5 mg/kg and tapered to a maintenance dose of 5 to 10 mg daily by 6 to 12 months, with some centers pursuing steroid-free regimens in selected patients.

Induction Therapy

Induction therapy, administered at the time of transplantation, provides intense early immunosuppression during the period of highest rejection risk. Basiliximab, a monoclonal antibody targeting the interleukin-2 receptor (anti-IL-2R), is the most commonly used induction agent and is administered perioperatively. Alemtuzumab (anti-CD52) produces potent and prolonged T-cell depletion through complement-dependent and antibody-dependent cell-mediated cytotoxicity and is used at some centers, particularly for patients considered at high immunologic risk. Anti-thymocyte globulin (ATG) provides potent T-cell depletion through polyclonal antibodies but is used less frequently due to its side effect profile, including cytokine release syndrome and prolonged lymphopenia.

Drug Interactions and Monitoring

Drug interaction management is a critical and ongoing challenge in post-transplant care. Tacrolimus is metabolized by the cytochrome P450 3A4 enzyme system, making it susceptible to numerous clinically significant drug interactions. Azole antifungals, particularly voriconazole, dramatically increase tacrolimus levels and typically necessitate a 50% to 75% reduction in tacrolimus dose when co-administered. Macrolide antibiotics and calcium channel blockers also increase tacrolimus levels, while rifampin and phenytoin decrease them through CYP3A4 induction. Regular monitoring of drug trough levels is essential given the narrow therapeutic index of calcineurin inhibitors: subtherapeutic levels increase the risk of rejection, while supratherapeutic levels increase nephrotoxicity and other adverse effects. Calcineurin inhibitor nephrotoxicity is the leading cause of chronic kidney disease in lung transplant recipients, necessitating regular surveillance of renal function.

Post-Transplant Complications

Primary Graft Dysfunction (PGD)

Primary graft dysfunction is the leading cause of early mortality following lung transplantation, typically manifesting within the first 72 hours. PGD represents the clinical consequence of ischemia-reperfusion injury: during the period of cold ischemic preservation and subsequent warm reperfusion, innate immune activation and endothelial damage produce a syndrome of non-cardiogenic pulmonary edema that is histologically and physiologically analogous to ARDS. The ISHLT grading system classifies PGD severity based on the PaO2/FiO2 ratio in the presence of bilateral radiographic infiltrates, with Grade 3 (PaO2/FiO2 less than 200) representing the most severe form.

Risk factors for PGD include high FiO2 during reperfusion, prolonged ischemic time, a history of donor smoking, high-risk donor characteristics, and recipient obesity. Management mirrors that of ARDS, with lung-protective ventilation, prone positioning, inhaled nitric oxide, and ECMO for severe cases. Importantly, PGD Grade 3 at 72 hours is an independent predictor of subsequent development of chronic lung allograft dysfunction, establishing a pathophysiologic link between early and late graft injury.

Acute Cellular Rejection (ACR)

Acute cellular rejection is most common during the first 6 to 12 months following transplantation, with an overall incidence of 30% to 50% in the first year. Clinically, patients present with dyspnea, cough, low-grade fever, and a decline in FEV1 from the post-transplant baseline. Diagnosis requires transbronchial biopsy, which is graded according to the ISHLT classification system: A-grade scores reflect perivascular rejection (A0 through A4, from no rejection to severe), while B-grade scores reflect airway rejection (B0 through B2R). A2 or higher-grade rejection is generally treated with pulse-dose methylprednisolone at 500 to 1000 mg intravenously daily for 3 days, followed by augmentation of the baseline immunosuppressive regimen. Recurrent episodes of acute cellular rejection represent a significant risk factor for chronic lung allograft dysfunction, and patients with recurrent rejection may require treatment with anti-thymocyte globulin, alemtuzumab, or protocol modifications.

Antibody-Mediated Rejection (AMR)

Antibody-mediated rejection has become increasingly recognized as an important cause of graft dysfunction in lung transplantation. The pathophysiology involves the development of donor-specific antibodies (DSA) targeting HLA antigens on the graft endothelium, leading to complement activation and microvascular injury. Histopathologic features include capillaritis and C4d complement fragment deposition on biopsy, combined with serologic evidence of DSA. Antibody-mediated rejection is associated with worse outcomes than isolated cellular rejection and is an independent risk factor for CLAD. Treatment approaches, which lack standardized protocols, include plasmapheresis to remove circulating antibodies, intravenous immunoglobulin, rituximab (anti-CD20 B-cell depletion), and bortezomib (proteasome inhibitor targeting antibody-producing plasma cells).

Chronic Lung Allograft Dysfunction (CLAD)

Chronic lung allograft dysfunction is the leading cause of long-term morbidity and mortality in lung transplant recipients, affecting approximately 50% of recipients by 5 years post-transplant. CLAD is defined as a persistent decline in FEV1 of 20% or greater from the post-transplant baseline, defined as the best of two post-transplant FEV1 measurements obtained at least 3 weeks apart.

CLAD is classified into distinct phenotypes with different pathologic features, radiographic appearances, and prognoses. Bronchiolitis obliterans syndrome (BOS), the most common phenotype accounting for approximately 70% of CLAD cases, manifests as progressive airflow limitation with obstructive physiology. The underlying pathology is fibroproliferative obliteration of the small airways, producing the histologic lesion of obliterative bronchiolitis. Restrictive allograft syndrome (RAS), a less common but more aggressive phenotype, is characterized by restrictive physiology with a decline in total lung capacity of 10% or greater. Radiographically, RAS produces upper-lobe fibrosis and a pleuroparenchymal fibroelastosis pattern, and it carries a significantly worse prognosis than BOS. A mixed phenotype with features of both BOS and RAS is also recognized.

Risk factors for CLAD include recurrent acute cellular rejection (especially recurrent episodes), antibody-mediated rejection and donor-specific antibodies, gastroesophageal reflux with microaspiration, cytomegalovirus infection, primary graft dysfunction (particularly Grade 3 at 72 hours), and community-acquired respiratory viral infections. Treatment options for established CLAD are unfortunately limited and largely ineffective at reversing the process. Augmentation of immunosuppression is attempted. Azithromycin at 250 mg daily may stabilize BOS in 25% to 40% of patients through anti-inflammatory and immunomodulatory mechanisms, and the BOSCALT protocol recommends initiation at the first sign of CLAD. Aggressive management of gastroesophageal reflux, including fundoplication for patients with documented reflux, may slow CLAD progression. Extracorporeal photopheresis is used at some centers with variable results. Re-transplantation is considered for selected patients but is limited by organ scarcity and the lower survival rates compared with primary transplant. Prevention strategies include prophylactic azithromycin (used as universal prophylaxis at some centers), aggressive treatment of acute rejection episodes, and early fundoplication for documented reflux.

<image>A comprehensive diagram of chronic lung allograft dysfunction (CLAD) phenotypes. Left panel: BOS (Bronchiolitis Obliterans Syndrome) - show cross-section of small airway with fibroproliferative obliteration of the lumen, surrounding normal alveoli; accompanying FEV1 trend graph showing progressive decline with obstruction pattern on PFTs; CT features (air trapping, mosaic attenuation). Right panel: RAS (Restrictive Allograft Syndrome) - show upper-lobe fibrosis with pleuroparenchymal thickening; accompanying FVC and TLC trend graphs showing restrictive decline; CT features (upper-lobe fibrosis, volume loss, ground glass). Center: risk factor diagram showing common risks for both (ACR, AMR/DSA, GERD, viral infections, PGD) converging on CLAD. Bottom: treatment options for each phenotype and their limited efficacy. Include 5-year survival curves comparing BOS vs. RAS (RAS has worse prognosis).</image>

Infectious Complications

Bacterial

Bacterial infections are the most common cause of infection in the early post-transplant period. Sources include donor-derived organisms transmitted with the graft, hospital-acquired pathogens from the perioperative and ICU period, and community-acquired bacteria encountered after discharge. The most frequently implicated organisms are Pseudomonas aeruginosa, Staphylococcus species, and Enterobacteriaceae. Prophylaxis involves perioperative broad-spectrum antibiotics tailored to local antibiograms, with culture-directed therapy in cystic fibrosis patients based on pre-transplant sputum cultures documenting their established microbial flora.

CMV (Cytomegalovirus)

Cytomegalovirus is the most important viral pathogen in lung transplantation and exerts both direct (end-organ disease) and indirect (immunomodulatory, promoting rejection and CLAD) effects. The highest risk combination is donor-positive/recipient-negative (D+/R-) serostatus, in which the immunologically naive recipient encounters CMV for the first time in the setting of profound immunosuppression. CMV pneumonitis presents with fever, hypoxemia, and ground glass opacities on CT. Two prophylactic strategies are employed: universal prophylaxis with valganciclovir at 450 to 900 mg daily for 6 to 12 months, or preemptive therapy in which CMV PCR viral load is monitored at regular intervals and antiviral therapy is initiated when viremia is detected. Treatment of established CMV disease consists of intravenous ganciclovir at 5 mg/kg every 12 hours, with CMV-specific intravenous immunoglobulin added in severe cases. Ganciclovir-resistant CMV should be suspected with persistent viremia despite adequate treatment and is confirmed by identifying UL97 and UL54 mutations; alternative agents include foscarnet and the newer agent maribavir.

Fungal

Aspergillus species are the most common fungal pathogens in lung transplant recipients, manifesting as anastomotic infection at the bronchial suture line, tracheobronchitis with pseudomembranous or ulcerative mucosal disease, or invasive pulmonary aspergillosis. Antifungal prophylaxis with voriconazole or itraconazole for 3 to 6 months post-transplant is standard practice, though the clinician must be vigilant about the significant interaction between azole antifungals and tacrolimus levels. Pneumocystis jirovecii pneumonia prophylaxis with trimethoprim-sulfamethoxazole (or alternative agents in intolerant patients) is maintained for the lifetime of the transplant recipient.

Other

Community-acquired respiratory viruses, including respiratory syncytial virus, influenza, parainfluenza, and rhinovirus, are important not only for their direct morbidity but also for their association with the subsequent development of CLAD. Epstein-Barr virus reactivation carries the risk of post-transplant lymphoproliferative disorder, particularly in EBV-seronegative recipients who receive organs from seropositive donors.

Post-Transplant Malignancy

The overall cancer risk in lung transplant recipients is 3 to 4 times that of the general population, driven by chronic immunosuppression. Skin cancer is the most common post-transplant malignancy, with squamous cell carcinoma predominating (in contrast to the general population where basal cell carcinoma is more common); all recipients should receive counseling on sun protection and undergo regular dermatologic screening. Post-transplant lymphoproliferative disorder (PTLD), an EBV-associated B-cell lymphoproliferative disorder, occurs in 3% to 8% of lung transplant recipients. Management involves reduction of immunosuppression as the initial step, with rituximab (anti-CD20 monoclonal antibody) and conventional chemotherapy for refractory or progressive disease. In single lung transplant recipients, the native lung retains its pre-transplant cancer risk, and lung cancer screening of the native lung is recommended.

Key Clinical Pearls

• IPF is now the most common indication for lung transplant and carries the highest waitlist mortality; early referral is critical, ideally when DLCO < 40% or FVC declining > 10% over 6 months
• CLAD (chronic rejection) affects ~50% of recipients by 5 years and remains the major barrier to long-term survival; BOS (obstructive) is more common but RAS (restrictive) has a worse prognosis
• Azithromycin 250 mg daily may stabilize BOS in 25-40% of patients through anti-inflammatory mechanisms and should be initiated early when CLAD is suspected
• CMV D+/R- (donor seropositive/recipient seronegative) mismatch is the highest-risk combination for CMV disease; universal prophylaxis with valganciclovir for at least 6-12 months is standard
• Post-transplant gastroesophageal reflux with aspiration is a major risk factor for CLAD; aggressive evaluation (impedance-pH monitoring, gastric emptying study) and treatment (fundoplication in appropriate candidates) should be considered early

References

1. Leard LE, Holm AM, Valapour M, et al. Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2021;40(7):573-612.
2. Chambers DC, Perch M, Zuckermann A, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 38th Adult Lung Transplant Report - 2021. J Heart Lung Transplant. 2021;40(10):1115-1130.
3. Verleden GM, Glanville AR, Lease ED, et al. Chronic lung allograft dysfunction: Definition, diagnostic criteria, and approaches to treatment - A consensus report from the Pulmonary Council of the ISHLT. J Heart Lung Transplant. 2019;38(5):493-503.
4. Snell GI, Yusen RD, Weill D, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading. J Heart Lung Transplant. 2017;36(10):1097-1103.
5. Cypel M, Yeung JC, Liu M, et al. Normothermic ex vivo lung perfusion in clinical lung transplantation. N Engl J Med. 2011;364(15):1431-1440.

Read this lecture as Markdown